Johnson & Johnson has entered into a definitive agreement to acquire Momenta Pharmaceuticals, Inc. for approximately $6.5 billion in cash.
This acquisition expands Janssen Pharmaceutical’s portfolio in immune-mediated diseases into autoantibody-driven disease. J&J gains global rights to nipocalimab (M281), a clinically validated, potentially best-in-class anti-FcRn antibody. Nipocalimab gives Janssen the opportunity to reach significantly more patients across many autoimmune disease indications, with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology.
